RxDoctor Payments Data

Pratik Sandesara, MD

Interventional Cardiology · Atlanta, GANPI 1033452354

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $103,746 of the $165,128 with a category attached, or 62.8%. 19 manufacturers reported payments, led by Boston Scientific at 52.0% of the total. 2025 is the largest year on record at $114,471, more than ten times the $3,315 reported in 2021. Among interventional cardiology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$165,128in general payments, 2019–2025

Across 487 payments — averaging $339.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$86K
  • Penumbra, Inc.$32K
  • Medtronic$16K
  • Asahi Intecc USA, Inc.$11K
  • Abbott$9K
  • Abiomed$5K
  • plus $7K from 13 others
$201,912in research payments, 2019–2025

Across 19 payments — averaging $10,627 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$114K
  • Shockwave Medical, Inc$53K
  • Arrow International, Inc.$35K

What the payments were for

  • Consulting fees$4,7383%
  • Speaking & faculty fees$103,74663%
  • Travel & lodging$31,36019%
  • Food & beverage$25,21215%
  • Education$720%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$165,128 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$208,413
Medicare patients
345
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$91,668
EntrestoSacubitril/Valsartan41$44,769
FarxigaDapagliflozin Propanediol30$41,976
BrilintaTicagrelor56$37,750
JardianceEmpagliflozin24$21,888
Repatha SureclickEvolocumab16$9,724
ClopidogrelClopidogrel Bisulfate446$4,545
Ranolazine ErRanolazine69$4,203
Prasugrel Hcl32$2,151
Atorvastatin Calcium199$1,810
Isosorbide Mononitrate ErIsosorbide Mononitrate133$1,661
Metoprolol Succinate128$1,173
Carvedilol91$636
Rosuvastatin Calcium67$599
Pantoprazole Sodium56$520

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →